February 12, 2024 11:16 AM EST
News Briefing

Im­muno­van­t's plans for au­toim­mune as­set; Wall Street wor­ries about Mod­er­na’s RSV can­di­date 

Max Gelman

Senior Editor

Ayisha Sharma

News Reporter

Jaimy Lee

Deputy Editor

Plus, news about No­vo Hold­ings, Grit­stone Bio, In­vivyd and Sci­ence 37:

Im­muno­vant out­lines big plans for its au­toim­mune pro­gram: The biotech

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times